Clinical Research Directory

Innovative Ovarian Cancer Biomarker Assays

Sponsor: National and Kapodistrian University of Athens

Summary

Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes. Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care. The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer. The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer. This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.

Official title: Multi-site, Multi-country Evaluation of Innovative Ovarian Cancer Biomarker Assays. (DISARM Clinical Study B-CSB)

Key Details

Conditions

Interventions

Locations (7)